[Moexipril and cardiovascular diseases in women: is there a reason for optimism?].

Abstract	Angiotensin converting enzyme (ACE) inhibitors are first line preparations in the treatment of chronic heart failure irrespective of etiology. However there are numerous proofs that in women drugs of this group exert less pronounced favorable prognostic influence compared with men. Moexipril is an ACE inhibitor which in women demonstrated its doubtless antihypertensive efficacy with additional favorable properties. The study of efficacy of moexipril in chronic heart failure in women is able to broaden indications to the use of this drug.
Authors
Journal	Kardiologiia (Kardiologiia) Vol. 46 Issue 7 Pg. 81-4 ( 2006) ISSN: 0022-9040 [Print] Russia (Federation)
PMID	16883271 (Publication Type: English Abstract, Journal Article, Review)
Chemical References	Angiotensin-Converting Enzyme Inhibitors Tetrahydroisoquinolines moexipril
Topics	Angiotensin-Converting Enzyme Inhibitors (therapeutic use) Cardiac Output, Low (drug therapy, etiology) Cardiovascular Diseases (drug therapy, etiology) Chronic Disease Female Humans Tetrahydroisoquinolines (chemistry, therapeutic use) Ventricular Remodeling (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!